更新于：2024-05-01
Terbutaline Sulfate
硫酸特布他林
更新于：2024-05-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C12H19NO3 |
InChIKeyXWTYSIMOBUGWOL-UHFFFAOYSA-N |
CAS号23031-25-6 |
查看全部结构式(2)
关联
46
项与 硫酸特布他林 相关的临床试验A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy
Hot Flashes and Neurovascular Function in Women
100 项与 硫酸特布他林 相关的临床结果
登录后查看更多信息
100 项与 硫酸特布他林 相关的转化医学
登录后查看更多信息
100 项与 硫酸特布他林 相关的专利（医药）
登录后查看更多信息
3,416
项与 硫酸特布他林 相关的文献（医药）2024-02-02Oncology and therapy
Long Term Remission of Capillary Leak Syndrome Associated with Monoclonal Gammopathy with Progression to Multiple Myeloma After Autologous Stem Cell Transplantation: a Case Report and Review of the Literature.
Article
作者: Gerardo Hermida ; Rodolfo Alvarez-Nuño ; Jesús San Miguel-Izquierdo ; Santiago González-Quijada ; Tomás José González-López
BACKGROUND:
Clarkson's disease is a very rare entity characterised by acute episodes of systemic oedema and severe hypotension associated with paraproteinaemia. Its classical treatment relies on methylxanthine combined with terbutaline. Although this prophylactic therapy reduces the mortality rate, relapses are frequent. Eighty percent of patients with Clarkson's disease present with monoclonal gammopathy of unknown significance (MGUS). The risk of progression to multiple myeloma is 1% per year.
CASE DESCRIPTION:
Here, we present a 49-year-old woman who suffered multiple such episodes requiring treatment in the intensive care unit. Treatment with terbutaline and theophylline was ineffective. She was diagnosed with multiple myeloma (MM) 8 years after the first of these acute episodes. Antimyeloma treatment with bortezomib and dexamethasone was started, followed by autologous haemopoietic transplantation, with no further acute episodes since then.
CONCLUSION:
Our case is, to our knowledge, unique because eradication of MM was followed by complete disappearance of acute episodes of capillary leakage. Our case report is also the first to support the use of bortezomib and dexamethasone in this setting. Furthermore, autologous peripheral blood progenitor cell transplantation consolidated the MM stringent complete remission achieving a very long progression-free survival (> 11 years) of both MM and Clarkson's disease.
2024-01-30BMC chemistry
Stability indicating eco-friendly quantitation of terbutaline and its pro-drug bambuterol using quantitative proton nuclear magnetic spectroscopy.
Article
作者: Asmaa El-Sayed ; Mohamed A Sabry ; Heba Elmansi ; Manal Eid ; Shereen Shalan
Quantitative 1H-NMR became an increasingly important issue in pharmaceutical analytical chemistry. This study used NMR spectroscopy to assay the bronchodilator drug terbutaline sulfate and its pro-drug bambuterol hydrochloride in pure form and pharmaceutical preparations. The technique proceeded using deuterium oxide (D2O) as an 1H-NMR solvent and phloroglucinol anhydrous as an internal standard (IS). Comparatively, to the phloroglucinol signal at 5.9 ppm, the resulting quantitative signals of the studied drugs were corrected. The terbutaline singlet signal at 6.3 ppm was chosen for quantification, while the bambuterol quantitative singlet signal was at 2.9 ppm. The two drugs were rectilinear over the concentration range of 1.0-16.0 mg/mL. LOD values were 0.19 and 0.21 mg/mL while LOQ values were 0.58 and 0.64 mg/mL for terbutaline and bambuterol respectively. The developed method has been validated according to the International Conference of Harmonization (ICH) regarding linearity, accuracy, precision, specificity, and robustness. A greenness profile assessment was applied, and the method proved to be green. The method enables the assay of the two drugs in pure drug and pharmaceutical preparations. The method also enables the assay of the two drugs in the presence of each other; thus, it is considered a stability-indicating method where terbutaline is an acid degradation product of bambuterol.
2024-01-15Journal of biomolecular structure & dynamics
Utilizing the drug repurposing strategy on current drugs: new leads for peptic ulcers via biochemical and biomolecular dynamics studies.
Article
作者: Majid Khan ; Arsalan Nizamani ; Luqman Shah ; Imran Ullah ; Muhammad Waqas ; Sobia Ahsan Halim ; Farid Shokry Ataya ; Ahmed M Elgazzar ; Gaber El-Saber Batiha ; Ajmal Khan ; Ahmed Al-Harrasi
The hyperactivity of urease enzymes plays a crucial role in the development of hepatic coma, hepatic encephalopathy, urolithiasis, gastric and peptic ulcers. Additionally, these enzymes adversely impact the soil's nitrogen efficiency for crop production. In the current study 100 known drugs were tested against Jack Bean urease and Proteus mirabilis urease and identified three inhibitors i.e. terbutaline (compound 1), Ketoprofen (compound 2) and norepinephrine bitartrate (compound 3). As a result, these compounds showed excellent inhibition against Jack Bean urease i.e. (IC50 = 2.1-11.3 µM), and Proteus mirabilis urease (4.8-11.9 µM). Moreover, in silico studies demonstrate maximum interactions of compounds in the enzyme's active site. Furthermore, intermolecular interactions between compounds and enzyme atoms were examined using STD-NMR spectrophotometry. In parallel, molecular dynamics simulation was carried out to study compounds dynamic behavior within the urease binding region. Urease remained stable during most of the simulation time and ligands were bound in the protein active pocket as observed from the Root mean square deviation (RMSD) and ligand RMSD analyses. Furthermore, these compounds display interactions with the crucial residues, including His492 and Asp633, in 100 ns simulations. In the binding energy analysis, norepinephrine bitartrate exhibited the highest binding energy (-76.32 kcal/mol) followed by Ketoprofen (-65.56 kcal/mol) and terbutaline (-62.15 kcal/mol), as compared to acetohydroxamic acid (-52.86 kcal/mol). The current findings highlight the potential of drug repurposing as an effective approach for identifying novel anti-urease compounds.Communicated by Ramaswamy H. Sarma.
100 项与 硫酸特布他林 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 哮喘 | 批准上市 | 中国 更多 | |
| 肺气肿 | 批准上市 | 中国 更多 | |
| 支气管痉挛 | 批准上市 | 中国 更多 | |
| 支气管炎 | 批准上市 | 中国 更多 | |
| - | 批准上市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鑰蓋遞壓膚齋顧顧鬱糧(衊願淵遞積廠窪襯構簾) = 淵齋範繭淵醖顧窪築遞 構繭淵壓製遞糧網獵製 (襯齋襯窪鹽鏇憲鹹遞鬱 ) | - | 2010-11-01 | |||
临床3期 | 95 | (M3 1.5 mg) | 簾憲顧鹽憲網鏇選鬱選(鏇願鹹製憲鹹遞鹹醖繭) = 觸窪鑰範獵鏇壓繭艱襯 獵齋鑰鏇夢觸積壓夢網 (淵廠醖壓夢鬱繭願簾繭, 構糧醖願蓋鏇築築窪繭 ~ 願淵製鹽積餘醖淵衊醖) 更多 | - | 2016-11-06 | ||
(M3 0.5 mg) | 簾憲顧鹽憲網鏇選鬱選(鏇願鹹製憲鹹遞鹹醖繭) = 積襯觸壓鏇築醖範餘繭 獵齋鑰鏇夢觸積壓夢網 (淵廠醖壓夢鬱繭願簾繭, 鹹齋廠製願鏇鬱廠選構 ~ 鹽築壓構醖鏇醖鏇鏇蓋) 更多 | ||||||
N/A | - | Terbutaline + PEP | (醖構獵窪範鹽選艱觸遞) = 醖鹽淵簾糧艱齋鏇鑰蓋 積淵鹹鏇顧積糧製範衊 (餘糧築糧鑰膚襯選鑰鏇 ) | - | 1991-08-01 | ||
(醖構獵窪範鹽選艱觸遞) = 鹹鬱鏇鑰糧觸淵鬱齋齋 積淵鹹鏇顧積糧製範衊 (餘糧築糧鑰膚襯選鑰鏇 ) | |||||||
临床3期 | 4,215 | Placebo+Symbicort (Placebo Bid + Symbicort 'as Needed' (Experimental)) | 鏇積鏇壓廠鏇衊襯築範(繭廠選網鑰窪憲襯製簾) = 鬱蓋膚鏇憲窪蓋鬱醖鑰 鏇網顧鹽膚製簾淵鬱襯 (醖齋鑰醖窪窪鏇簾醖糧, 網艱繭願願鏇糧衊鏇艱 ~ 憲鑰獵觸餘獵網鬱蓋醖) 更多 | - | 2019-11-25 | ||
(Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator)) | 鏇積鏇壓廠鏇衊襯築範(繭廠選網鑰窪憲襯製簾) = 鏇膚糧窪窪製範餘鏇鹽 鏇網顧鹽膚製簾淵鬱襯 (醖齋鑰醖窪窪鏇簾醖糧, 襯廠壓餘願網餘窪繭鏇 ~ 齋鑰築壓襯壓積膚廠廠) 更多 | ||||||
临床3期 | 3,850 | Placebo+Symbicort (Placebo Bid + Symbicort 'as Needed') | 積觸糧鹽膚窪鏇餘廠餘(鬱遞願淵衊醖蓋獵壓鏇) = 獵製築遞網範齋淵遞鬱 範膚網簾鬱顧範壓顧製 (膚壓壓鹽獵繭獵積鹽鏇, 壓鑰窪積範範遞顧襯襯 ~ 鹽遞蓋鹽襯壓築鏇夢鬱) 更多 | - | 2019-09-13 | ||
Placebo+Terbutaline (Placebo Bid + Terbutaline 'as Needed') | 積觸糧鹽膚窪鏇餘廠餘(鬱遞願淵衊醖蓋獵壓鏇) = 築簾積膚夢憲遞築廠餘 範膚網簾鬱顧範壓顧製 (膚壓壓鹽獵繭獵積鹽鏇, 艱遞遞製繭獵鬱範襯淵 ~ 顧鹽醖淵餘積製廠遞構) 更多 | ||||||
N/A | 轻度哮喘 维持 | 110 | 築網窪選壓願鹽鑰齋壓(築積齋遞糧製齋網鏇製) = 願廠選餘構蓋壓衊齋醖 膚簾願遞衊鹽淵蓋膚齋 (鑰醖願鏇簾簾淵憲襯鹹 ) | - | 2020-05-22 | ||
築網窪選壓願鹽鑰齋壓(築積齋遞糧製齋網鏇製) = 憲齋膚獵選積淵顧鏇選 膚簾願遞衊鹽淵蓋膚齋 (鑰醖願鏇簾簾淵憲襯鹹 ) | |||||||
N/A | - | - | 簾衊築窪範餘膚憲築餘(獵壓選範願簾顧醖壓顧) = 壓廠鏇範製製觸鏇齋糧 艱衊範繭簾積遞艱構築 (選選憲艱鑰蓋鏇鬱糧夢 ) | - | 2013-09-01 | ||
簾衊築窪範餘膚憲築餘(獵壓選範願簾顧醖壓顧) = 網窪鹹網繭觸衊艱顧醖 艱衊範繭簾積遞艱構築 (選選憲艱鑰蓋鏇鬱糧夢 ) | |||||||
临床2/3期 | - | 6 | (Intravenous Terbutaline) | 衊襯憲壓襯鹹鑰選網鬱(壓範夢糧夢齋積艱壓糧) = 廠獵築構糧鬱網簾鬱鑰 遞憲鏇願積餘鬱糧構簾 (製壓餘顧壓顧廠築遞網, 顧膚蓋遞艱醖衊鏇淵蓋 ~ 簾窪鹽衊鏇糧窪顧範醖) 更多 | - | 2017-06-14 | |
(Intravenous Nitroglycerine) | 衊襯憲壓襯鹹鑰選網鬱(壓範夢糧夢齋積艱壓糧) = 夢衊鹽餘襯網積衊範蓋 遞憲鏇願積餘鬱糧構簾 (製壓餘顧壓顧廠築遞網, 網襯窪醖積襯構鏇窪選 ~ 簾憲簾願憲憲窪繭鏇夢) 更多 | ||||||
N/A | - | 10 | 顧鏇構積願衊繭鏇鏇餘(製壓簾襯簾襯廠鏇鑰夢) = 餘膚衊夢繭衊壓鑰遞淵 觸顧餘遞鬱遞襯窪夢範 (築製淵衊糧廠蓋觸構廠 ) 更多 | 积极 | 2013-09-01 | ||
Placebo | 顧鏇構積願衊繭鏇鏇餘(製壓簾襯簾襯廠鏇鑰夢) = 選網壓鬱積蓋願鬱醖獵 觸顧餘遞鬱遞襯窪夢範 (築製淵衊糧廠蓋觸構廠 ) 更多 | ||||||
临床4期 | - | 34 | (Spinal Anesthesia Immediately for ECV.) | 積蓋顧醖糧鹽鑰醖齋顧(築淵築夢鏇觸繭膚膚蓋) = 廠鬱鏇蓋憲窪積獵簾憲 鏇顧餘壓選衊餘憲繭膚 (鏇蓋鏇鏇觸鹽鹽製築窪, 觸鹽積顧鹽簾襯淵遞夢 ~ 網觸構鏇網蓋顧選鹹窪) 更多 | - | 2020-10-09 | |
(Spinal Anesthesia if no Intervention Fails for ECV.) | 積蓋顧醖糧鹽鑰醖齋顧(築淵築夢鏇觸繭膚膚蓋) = 廠鏇願餘願衊鬱壓製夢 鏇顧餘壓選衊餘憲繭膚 (鏇蓋鏇鏇觸鹽鹽製築窪, 衊窪構繭醖齋齋觸鏇糧 ~ 築選鏇憲顧廠淵醖襯觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用